Global Hematology and Coagulation Testing Markets Report 2020 with Discussion of COVID-19
October 28, 2020 06:53 ET
|
Research and Markets
Dublin, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The "Hematology and Coagulation Markets (Lab-based and Decentralized Markets)" report has been added to ResearchAndMarkets.com's offering. Hematology and...
NIH Awards Prize to Hemex Health’s Non-Invasive Sickle Cell, Malaria, Anemia Rapid Test (“SMART”) Diagnostic Technology
October 26, 2020 08:00 ET
|
Hemex Health
PORTLAND, Ore., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Researchers from Hemex Health, Medtronic plc, Case Western Reserve University, and the University of Nebraska Medical Center’s International...
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia
October 16, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Report [2020-2026] Sickle Cell Disease Treatment Market Size, Share, Growth, Trends, Analysis, Competitive Landscape, Forecast by Fortune Business Insights™
October 13, 2020 07:07 ET
|
Fortune Business Insights
Pune, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Increasing impetus to research on gene therapy to treat sickle cell disease is a key factor contributing to the global sickle cell disease treatment market,...
Imara to Present at Upcoming Investor Conferences
September 02, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease
August 25, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports Second Quarter 2020 Financial Results and Business Highlights
August 14, 2020 07:00 ET
|
Imara, Inc.
Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial Reported Phase 2a interim safety and...
Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
August 13, 2020 16:01 ET
|
Imara, Inc.
BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
August 07, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Cyclerion Therapeutics Completes $24 Million Private Placement
July 30, 2020 09:00 ET
|
Cyclerion Therapeutics, Inc.
- Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease - - IW-6463 translational pharmacology and olinciguat STRONG Phase...